Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
April 30, 2018 16:00 ET
|
Apellis Pharmaceuticals, Inc.
- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public...
Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
April 23, 2018 18:20 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
April 18, 2018 21:26 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
April 16, 2018 17:12 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
April 16, 2018 09:23 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
March 19, 2018 16:30 ET
|
Apellis Pharmaceuticals, Inc.
- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
February 22, 2018 08:44 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 02, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
December 20, 2017 17:30 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...